Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Duloxetine Hydrochloride Clear all
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Withdrawn Phase 4 Interventional

Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery

NCT02351440
View directory record Official record
Conditions
Quality of Recovery, Gynecologic Surgery, Laparoscopy
Interventions
duloxetine, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00366652
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
desvenlafaxine SR, desipramine, duloxetine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2007 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)

NCT03315533
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Duloxetine 30 milligrams (MG), Duloxetine 60 milligrams (MG), Placebo Oral Tablet
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

NCT00190866
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

NCT00696293
View directory record Official record
Conditions
Major Depressive Disorder, Back Pain, Aged
Interventions
Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 2, 2026, 2:43 PM EDT
Withdrawn Phase 4 Interventional

A Study for Adolescents With Fibromyalgia Syndrome

NCT01089621
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fairfield, Connecticut • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 2, 2026, 2:43 PM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Not applicable Interventional Results available

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

NCT01028352
View directory record Official record
Conditions
Breast Cancer
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
32
States / cities
Tucson, Arizona • Garden Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 2, 2026, 2:43 PM EDT
Withdrawn Phase 2 Interventional

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

NCT02857244
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Duloxetine, Donepezil, Modafinil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 2, 2026, 2:43 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Duloxetine on Male Fertility

NCT03038867
View directory record Official record
Conditions
Infertility, Male, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 2, 2026, 2:43 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107
View directory record Official record
Conditions
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
792
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

NCT03575403
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol, Placebos, Duloxetine (60 MG), Methylphenidate, Duloxetine (30 MG)
Drug
Lead sponsor
Craig Rush
Other
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine for Chronic Depression: a Double-blind Study

NCT00360724
View directory record Official record
Conditions
Dysthymic Disorder, Depressive Disorder NOS
Interventions
Duloxetine (Cymbalta)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Painful Diabetic Neuropathy

NCT00058968
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Pembroke Pines, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 2, 2026, 2:43 PM EDT
Withdrawn Phase 1 Interventional

Enhancing Processing Speed and Executive Functioning in Depressed Older Adults With Computerized Cognitive Training

NCT04836533
View directory record Official record
Conditions
Depression in Old Age, Depression
Interventions
Experimental: Computerized Cognitive Training, Experimental: Open-label antidepressant treatment, Active Comparator: Solitaire Training, Placebo Comparator: Placebo-controlled antidepressant treatment
Other · Drug
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 2, 2026, 2:43 PM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 2, 2026, 2:43 PM EDT